OBJECTIVES: To evaluate the relationship of hormone (estrogen receptor alpha, estrogen receptor beta, progesterone receptor) and growth factor receptor (insulin-like growth factor receptor, human epidermal growth factor receptor 2) expression with disease progression in uterine carcinosarcoma. STUDY DESIGN: Immunohistochemistry was performed on tissue arrays using standard methodology. Differences between groups were evaluated by the Wilcoxon rank-sum test. Interactions between tumor stage and receptor expression were determined by linear trend analysis. RESULTS: Compared with normal endometrium, carcinosarcomas exhibited low estrogen receptor alpha and progesterone receptor expression (all P < .01), but overexpressed estrogen receptor beta (P = .02). Estrogen receptor beta expression increased in advanced stage disease (P = .02). Insulin-like growth factor receptor expression was lower in carcinosarcoma compared with normal endometrium (P = .01). Human epidermal growth factor receptor 2 expression was elevated and increased with disease progression (P < .01). CONCLUSION: In uterine carcinosarcoma, estrogen receptor beta expression is elevated and increases with disease progression, whereas estrogen receptor alpha and progesterone receptor are suppressed. Human epidermal growth factor receptor 2 expression is increased, whereas insulin-like growth factor receptor is lower than in normal endometrium. These data support a potential role for estrogen receptor beta in disease progression via crosstalk with human epidermal growth factor receptor 2.
OBJECTIVES: To evaluate the relationship of hormone (estrogen receptor alpha, estrogen receptor beta, progesterone receptor) and growth factor receptor (insulin-like growth factor receptor, human epidermal growth factor receptor 2) expression with disease progression in uterine carcinosarcoma. STUDY DESIGN: Immunohistochemistry was performed on tissue arrays using standard methodology. Differences between groups were evaluated by the Wilcoxon rank-sum test. Interactions between tumor stage and receptor expression were determined by linear trend analysis. RESULTS: Compared with normal endometrium, carcinosarcomas exhibited low estrogen receptor alpha and progesterone receptor expression (all P < .01), but overexpressed estrogen receptor beta (P = .02). Estrogen receptor beta expression increased in advanced stage disease (P = .02). Insulin-like growth factor receptor expression was lower in carcinosarcoma compared with normal endometrium (P = .01). Human epidermal growth factor receptor 2 expression was elevated and increased with disease progression (P < .01). CONCLUSION: In uterine carcinosarcoma, estrogen receptor beta expression is elevated and increases with disease progression, whereas estrogen receptor alpha and progesterone receptor are suppressed. Human epidermal growth factor receptor 2 expression is increased, whereas insulin-like growth factor receptor is lower than in normal endometrium. These data support a potential role for estrogen receptor beta in disease progression via crosstalk with human epidermal growth factor receptor 2.
Authors: Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein Journal: Gynecol Oncol Date: 2007-10-23 Impact factor: 5.482
Authors: W. G. McCluggage; M. Abdulkader; J. H. Price; P. Kelehan; S. Hamilton; J. Beattie; A. Al-Nafussi Journal: Int J Gynecol Cancer Date: 2000-07 Impact factor: 3.437
Authors: Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Jenna Z Marcus; Merieme Klobocista; Rouzan G Karabakhtsian; Eric Prossnitz; Gary L Goldberg; Gloria S Huang Journal: Int J Gynecol Cancer Date: 2018-03 Impact factor: 3.437
Authors: Gloria S Huang; Marc J Gunter; Rebecca C Arend; Maomi Li; Hugo Arias-Pulido; Eric R Prossnitz; Gary L Goldberg; Harriet O Smith Journal: Am J Obstet Gynecol Date: 2010-06-03 Impact factor: 8.661
Authors: P Martin-Romano; M Jurado; M A Idoate; L Arbea; J L Hernandez-Lizoain; D Cano; J A Paramo; S Martin-Algarra Journal: J Med Case Rep Date: 2017-04-19